Seven Eight Capital’s CG Oncology CGON Stock Holding History

Seven Eight Capital’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,744	Closed	-$481K	–	121
2024 Q3	$481K	Buy	+12,744	New	+$447K	0.04%	567

Other funds holding CGON

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Seven Eight Capital's CGON Position: Q4 2024 in Review

Seven Eight Capital sold out of CG Oncology (CGON) in Q4 2024, closing a stake of 12,744 shares — an estimated $481K sold.

Seven Eight Capital first reported a position in CGON in Q3 2024 and held it in 1 quarter. The position peaked at $481K in Q3 2024. 140 funds tracked by Wall St. Rank hold CGON as of Q4 2024.

Seven Eight Capital reported no remaining CG Oncology position as of Q4 2024 after selling out during the quarter.
Seven Eight Capital sold 12,744 CG Oncology shares in Q4 2024, an estimated $481K.
Seven Eight Capital first reported a position in CG Oncology in Q3 2024 and held it in 1 quarter.
Seven Eight Capital's CG Oncology position peaked at $481K in Q3 2024.
140 funds tracked by Wall St. Rank held CG Oncology as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.